EyePoint Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (EYPT)

Historical Holders from Q4 2020 to Q3 2025

Symbol
EYPT on Nasdaq
CUSIP
30233G209
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
68.9M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
69.4M
Holdings value
$988M
% of all portfolios
0.003%
Grand Portfolio weight change
+0%
Number of holders
146
Number of buys
68
Number of sells
-62
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of EyePoint Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (EYPT)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Adage Capital Management, L.P. 8.07% -18.1% $79.2M -$17.7M 5.56M -18.2% Adage Capital Management, L.P. Sep 30, 2025
FEDERATED HERMES, INC. 6.68% $27.2M 4.6M Federated Hermes, Inc. Jun 30, 2025
BlackRock, Inc. 6.5% $63.9M 4.49M BlackRock, Inc. Sep 30, 2025
FRANKLIN RESOURCES INC 6.1% -17.5% $19.1M $580K 4.14M +3.13% Franklin Resources, Inc. Dec 31, 2024
RA CAPITAL MANAGEMENT, L.P. 4.7% $14.7M 3.18M RA Capital Management, L.P. Dec 31, 2024

Institutional Holders of EyePoint Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (EYPT)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 69.4M $988M +$20.2M $14.24 146
2025 Q2 68.9M $648M -$21.9M $9.41 139
2025 Q1 74.1M $401M -$6.56M $5.42 149
2024 Q4 74.3M $553M +$114M $7.45 141
2024 Q3 58.5M $476M -$4.31M $7.99 136
2024 Q2 58.4M $508M +$27.4M $8.70 150
2024 Q1 5.12M $106M -$41.2M $20.67 30
2023 Q4 34.7K $803K -$577K $23.11 2
2023 Q3 33.7M $269M +$16.7M $7.99 97
2023 Q2 31.6M $275M +$22.9M $8.70 82
2023 Q1 29.1M $85.6M -$1.21M $2.94 66
2022 Q4 29.4M $103M -$6.52M $3.50 71
2022 Q3 29.2M $231M +$33.4K $7.91 79
2022 Q2 29.2M $230M +$661K $7.87 75
2022 Q1 30.1M $366M +$7.72M $12.15 74
2021 Q4 29.8M $365M +$95.1M $12.24 85
2021 Q3 22.1M $230M +$15M $10.42 62
2021 Q2 20.7M $186M +$7.94M $8.99 60
2021 Q1 19.6M $200M +$124M $10.16 58
2020 Q4 7.7M $50.7M +$50.7M $6.58 33